MybestPicksEver - FOCUS ON FACTS - Cord Blood America Inc. (CBAI)
Though the idea of stem cells are a relatively new idea and people don’t know much about them, the work that CorCell Companies Inc. has done in this industry can be considered by many to be mind-blowing. "An Invesment For The Future"
(EMAILWIRE.COM, August 27, 2010 ) New York,NY - Cord Blood America Inc. (CBAI)
Engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. A great comparison is to look at the cord blood that is preserved as an insurance policy for your newborn, as it provides the family a strong peace of mind, in case of a medical emergency, the knowledge that the cells are available is readily available and can assist in saving your child / family members life.
Stem cell is essentially a ‘blank’ cell, capable of becoming another more differentiated cell type in the body, such as a skin cell, a muscle cell, or a nerve cell. Microscopic in size, stem cells are big news in the medical and science circles because they can be used to replace or even heal damaged tissues and cells in the body.
They can serve as a built-in repair system for the human body, replenishing other cells as long as a person is still alive. Umbilical cord blood is the blood that remains in the placenta and in the attached umbilical cord after child birth. Cord blood is collected because it contains stem cells, including hematopoietic cells (HSC – The HSC cells are used in bone marrow transplantations, as it is known that a small number of HSCs can expand to generate a very large number of ‘daughter’ HSCs.), which can be used to treat hematopoietic and genetic disorders, and the hepcrotanic stem cells prematurely clamped.
Removal of the umbilical cord blood is not harmful to the baby in any way, and the blood would normally be thrown away as medical waste. A huge advantage to harvesting umbilical cord blood is that, like harvesting adult stem cells, there are currently no ethical draw backs. Without these draw backs, research can move forward at a more rapid pace than embryonic stem cell research, which for many people has ethical draw backs.
Methods most commonly used in clinical practice is the ‘closed technique’ which is similar to standard blood collection techniques. With this method, the technician cannulates the vein of the severed umbilical cord using a needle that is connected to a blood bag, and cord blood flows through the needle into the bag. On average, the closed technique enables collection of about 75 ml of cord blood. Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation.
Although umbilical cord blood is well recognized to be useful for treating hematopietic and genetic disorders, some controversy surrounds the collection and storage of umbilical cord blood by private banks for the baby’s use. Only a small percentage of babies (estimated at between 1:1000 to 1:200,000) ever use the umbilical cord blood that is stored. It is recommended for those who have a family history of specific genetic diseases.
For more Information Visit: http://www.mybestpicksever.com
There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. CBAI, through CorCell, markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive.
Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.
Besides current uses, medical research is ongoing on how to use these cells to combat heart disease, Parkinson’s disease, spinal cord injuries, sickle cell anemia, cancer and other difficult diseases to treat. Researchers postulate that the cells they remove from the umbilical cord blood can someday be turned into every single tissue in the body, making, for instance, the repair of a damaged heart possible, or facilitating recovery from a stroke by turning stem cells into brain cells.
Cord Blood America had recently had their second quarter financial review and it was noted that their revenues increased approximately 12% to $951,561 compared to $813,950 in the same period in 2009. Revenue increased due to Cord Blood America purchase of Fifty One percent of the total outstanding shares of stellacure GmbH, a private German company which collects, processes and stores cord blood for use in Germany, Spain and other European and middle Eastern countries.
Revenues rose to $1.79 million, up from $1.76 million in the first half of 2009.
Cord Blood America’s strategy is specifically focused on top line growth. They will accomplish this through their ‘Three pillars of success” strategy:
1) Organic Growth
2) Acquisitions and
3) Diversification of Revenue Streams
CBAI offers the proverbial once in a lifetime opportunity. You can’t give birth to the same child twice. For organic growth, marketing and education is such an important factor in this sector. CBAI has assembled an experienced marketing team second to none in the industry, and coupled this team in health insurer partnerships.
CBAI has nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of that parent’s pregnancy. This is a growth industry: Only a few years ago, five percent of the four million women in the U.S. giving birth knew about preserving their umbilical cord blood and two percent of these took advantage of this lifesaving procedure. The number of cord blood samples stored has since been growing by 50 percent a year, and more than four percent of all those giving birth now preserve the umbilical cord. CBAI intends to be number one in educating about the advantages of these cord blood banking services and then to be the top performer in signing new families to utilize its services. The Company already had revenues topping $4.2 Million in 2008.
In addition to organic growth, CBAI believes that acquisition of revenue streams is as important to contribution to the top line. CBAI has stated repeatedly that it has a large appetite for acquisitions with annuity streams, and will continue to vigorously pursue these in 2010. For the third “pillar”, CBAI intends to be one of the largest cryogenic storage facilities in the world. The Company completed construction of a 17,000 square foot facility in Las Vegas, Nevada. Our facility has the capacity for storage of more than 250,000 blood and tissue samples. When that capacity is reached.
CBAI will build another one. With the large facility, CBAI will introduce processing and storage of other cell and tissue samples, such as adipose and peripheral blood stem cells, further diversifying its revenue streams.
In recent news, the California institute for Regenerative medicine approved the concept for up to $243 million in funding to move stem cell-based therapies into clinical trials. The funding round represents the second in a recurring round of funding intended to support multidisciplinary teams of researchers working toward filing a request to begin clinical trials or completing Phase I or II studies within four years. Another great step for stem cell within the research community!
A heart wrenched story about a girl named Natalie Curry, who was saved by a cord blood transplant from one of her younger sisters.
(thanks to her sister Emily).
You can read more about their story on: http://nataliecurry.com/my-story/
Technical data for Cord Blood America, Inc. (CBAI)
Based on the last 24 trading days, here is the data found:
Average Open Price: $0.0053
Average High Price: $0.0055
Average Low Price: $0.0051
Average Close Price: $0.0052
Average Volume: 19,296,044.33 shares
Based on the last 1 year of trading (253 trading days), here is the data found:
Highest Volume day: 09/30/2009
Highest Volume: 1,210,249,472
52 week high date: 01/08/2010
52 week high price: $0.0197
52 week low date: 09/01/2009
52 week low price: $0.0029
Average Open Price: $0.0074
Average High Price: $0.0077
Average Low price: $0.007
Average Close price: $0.0073
Average Volume: 90,511,707.49 shares
Largest % gain: 77.42%
Largest % gain day: 09/28/2009
Price jump: $0.0033 à $0.0055 (high on that day was $0.0062)
Largest % loss: – 28.28%
Large % loss day: 10/01/2009
Price Jump: $0.0102 à $0.0071
Close as of 08/20/2010 was $0.0049 (down approximately 2% trading on lower than average volume 17.49M shares)
Based on the numbers above, today’s stock price represents the company’s stock price at an approximately 40% premium (basically, in order to get the price to its 52 week high, we would need to see the current price jump 40x)
Based on a 10 day chart:
Money Flow Index – 14
Showing 52.46 as of close today, 08/20/2010
RSI – 14
Showing 43.48 as of close today, 08/20/2010
MACD (7,14) EMA (10)
Great range showing here as the two lines crossed downwards around the end of the day on Thursday, 08/19/2010 and continued to move slightly down throughout the day on Friday, August 20, 2010. Based on the previous days, the divergence has narrowed in a little and may show a move for and upward movement in the coming days.
A 1 year chart looks like it peaked out at the beginning of the year, and took a tumble, but has slowly worked its way off its 52 week lows. Still at a bargain price, we can see some potential in the upcoming months as stem cell research continues to get more popular and more funding.
Umbilical Cord Blood is the future for Stem Cell Research as it is ethically correct, and has shown great signs for the future of the industry. With great stories like Natalie Curry, seeing that a child could suffer so much and without the assistance of her sisters Stem Cells, she would not be around today. CorCells Companies Inc. has the knowledge and understanding to move this business forward and revolutionize the medical industry. President Obama has taken such an interest when he got elected that back in 2009 he ended the ban on Stem cell research. As stated back in March, 2009 “Medical Miracles do not happen simple by accident”.
With such an endorsement, by the President of the United States of America, Stem Cell research has a future, and the company that will shine amongst the rest will be Cord Blood America (CBAI).
Visit us at: http://www.mybestpicksever.com
Disclaimer
MyBestPicksEver.Com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. All information provided on this website pertaining to investing, stocks, securities must be understood as information provided and not investment advice. We advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks any stock including those featured on MyBestPicksEver.Com
Engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. A great comparison is to look at the cord blood that is preserved as an insurance policy for your newborn, as it provides the family a strong peace of mind, in case of a medical emergency, the knowledge that the cells are available is readily available and can assist in saving your child / family members life.
Stem cell is essentially a ‘blank’ cell, capable of becoming another more differentiated cell type in the body, such as a skin cell, a muscle cell, or a nerve cell. Microscopic in size, stem cells are big news in the medical and science circles because they can be used to replace or even heal damaged tissues and cells in the body.
They can serve as a built-in repair system for the human body, replenishing other cells as long as a person is still alive. Umbilical cord blood is the blood that remains in the placenta and in the attached umbilical cord after child birth. Cord blood is collected because it contains stem cells, including hematopoietic cells (HSC – The HSC cells are used in bone marrow transplantations, as it is known that a small number of HSCs can expand to generate a very large number of ‘daughter’ HSCs.), which can be used to treat hematopoietic and genetic disorders, and the hepcrotanic stem cells prematurely clamped.
Removal of the umbilical cord blood is not harmful to the baby in any way, and the blood would normally be thrown away as medical waste. A huge advantage to harvesting umbilical cord blood is that, like harvesting adult stem cells, there are currently no ethical draw backs. Without these draw backs, research can move forward at a more rapid pace than embryonic stem cell research, which for many people has ethical draw backs.
Methods most commonly used in clinical practice is the ‘closed technique’ which is similar to standard blood collection techniques. With this method, the technician cannulates the vein of the severed umbilical cord using a needle that is connected to a blood bag, and cord blood flows through the needle into the bag. On average, the closed technique enables collection of about 75 ml of cord blood. Collected cord blood is cryopreserved and then stored in a cord blood bank for future transplantation.
Although umbilical cord blood is well recognized to be useful for treating hematopietic and genetic disorders, some controversy surrounds the collection and storage of umbilical cord blood by private banks for the baby’s use. Only a small percentage of babies (estimated at between 1:1000 to 1:200,000) ever use the umbilical cord blood that is stored. It is recommended for those who have a family history of specific genetic diseases.
For more Information Visit: http://www.mybestpicksever.com
There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. CBAI, through CorCell, markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive.
Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.
Besides current uses, medical research is ongoing on how to use these cells to combat heart disease, Parkinson’s disease, spinal cord injuries, sickle cell anemia, cancer and other difficult diseases to treat. Researchers postulate that the cells they remove from the umbilical cord blood can someday be turned into every single tissue in the body, making, for instance, the repair of a damaged heart possible, or facilitating recovery from a stroke by turning stem cells into brain cells.
Cord Blood America had recently had their second quarter financial review and it was noted that their revenues increased approximately 12% to $951,561 compared to $813,950 in the same period in 2009. Revenue increased due to Cord Blood America purchase of Fifty One percent of the total outstanding shares of stellacure GmbH, a private German company which collects, processes and stores cord blood for use in Germany, Spain and other European and middle Eastern countries.
Revenues rose to $1.79 million, up from $1.76 million in the first half of 2009.
Cord Blood America’s strategy is specifically focused on top line growth. They will accomplish this through their ‘Three pillars of success” strategy:
1) Organic Growth
2) Acquisitions and
3) Diversification of Revenue Streams
CBAI offers the proverbial once in a lifetime opportunity. You can’t give birth to the same child twice. For organic growth, marketing and education is such an important factor in this sector. CBAI has assembled an experienced marketing team second to none in the industry, and coupled this team in health insurer partnerships.
CBAI has nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of that parent’s pregnancy. This is a growth industry: Only a few years ago, five percent of the four million women in the U.S. giving birth knew about preserving their umbilical cord blood and two percent of these took advantage of this lifesaving procedure. The number of cord blood samples stored has since been growing by 50 percent a year, and more than four percent of all those giving birth now preserve the umbilical cord. CBAI intends to be number one in educating about the advantages of these cord blood banking services and then to be the top performer in signing new families to utilize its services. The Company already had revenues topping $4.2 Million in 2008.
In addition to organic growth, CBAI believes that acquisition of revenue streams is as important to contribution to the top line. CBAI has stated repeatedly that it has a large appetite for acquisitions with annuity streams, and will continue to vigorously pursue these in 2010. For the third “pillar”, CBAI intends to be one of the largest cryogenic storage facilities in the world. The Company completed construction of a 17,000 square foot facility in Las Vegas, Nevada. Our facility has the capacity for storage of more than 250,000 blood and tissue samples. When that capacity is reached.
CBAI will build another one. With the large facility, CBAI will introduce processing and storage of other cell and tissue samples, such as adipose and peripheral blood stem cells, further diversifying its revenue streams.
In recent news, the California institute for Regenerative medicine approved the concept for up to $243 million in funding to move stem cell-based therapies into clinical trials. The funding round represents the second in a recurring round of funding intended to support multidisciplinary teams of researchers working toward filing a request to begin clinical trials or completing Phase I or II studies within four years. Another great step for stem cell within the research community!
A heart wrenched story about a girl named Natalie Curry, who was saved by a cord blood transplant from one of her younger sisters.
(thanks to her sister Emily).
You can read more about their story on: http://nataliecurry.com/my-story/
Technical data for Cord Blood America, Inc. (CBAI)
Based on the last 24 trading days, here is the data found:
Average Open Price: $0.0053
Average High Price: $0.0055
Average Low Price: $0.0051
Average Close Price: $0.0052
Average Volume: 19,296,044.33 shares
Based on the last 1 year of trading (253 trading days), here is the data found:
Highest Volume day: 09/30/2009
Highest Volume: 1,210,249,472
52 week high date: 01/08/2010
52 week high price: $0.0197
52 week low date: 09/01/2009
52 week low price: $0.0029
Average Open Price: $0.0074
Average High Price: $0.0077
Average Low price: $0.007
Average Close price: $0.0073
Average Volume: 90,511,707.49 shares
Largest % gain: 77.42%
Largest % gain day: 09/28/2009
Price jump: $0.0033 à $0.0055 (high on that day was $0.0062)
Largest % loss: – 28.28%
Large % loss day: 10/01/2009
Price Jump: $0.0102 à $0.0071
Close as of 08/20/2010 was $0.0049 (down approximately 2% trading on lower than average volume 17.49M shares)
Based on the numbers above, today’s stock price represents the company’s stock price at an approximately 40% premium (basically, in order to get the price to its 52 week high, we would need to see the current price jump 40x)
Based on a 10 day chart:
Money Flow Index – 14
Showing 52.46 as of close today, 08/20/2010
RSI – 14
Showing 43.48 as of close today, 08/20/2010
MACD (7,14) EMA (10)
Great range showing here as the two lines crossed downwards around the end of the day on Thursday, 08/19/2010 and continued to move slightly down throughout the day on Friday, August 20, 2010. Based on the previous days, the divergence has narrowed in a little and may show a move for and upward movement in the coming days.
A 1 year chart looks like it peaked out at the beginning of the year, and took a tumble, but has slowly worked its way off its 52 week lows. Still at a bargain price, we can see some potential in the upcoming months as stem cell research continues to get more popular and more funding.
Umbilical Cord Blood is the future for Stem Cell Research as it is ethically correct, and has shown great signs for the future of the industry. With great stories like Natalie Curry, seeing that a child could suffer so much and without the assistance of her sisters Stem Cells, she would not be around today. CorCells Companies Inc. has the knowledge and understanding to move this business forward and revolutionize the medical industry. President Obama has taken such an interest when he got elected that back in 2009 he ended the ban on Stem cell research. As stated back in March, 2009 “Medical Miracles do not happen simple by accident”.
With such an endorsement, by the President of the United States of America, Stem Cell research has a future, and the company that will shine amongst the rest will be Cord Blood America (CBAI).
Visit us at: http://www.mybestpicksever.com
Disclaimer
MyBestPicksEver.Com is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. All information provided on this website pertaining to investing, stocks, securities must be understood as information provided and not investment advice. We advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks any stock including those featured on MyBestPicksEver.Com
Contact Information:
MyBestPicksEver
Chris Wick
Tel: 905-581-5778
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
MyBestPicksEver
Chris Wick
Tel: 905-581-5778
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |